New cancer drug targets notorious KRAS mutation in first human trial
Disease control
Not yet recruiting
This is an early-stage study to test the safety and initial effects of a new drug called ABO2102 in adults with advanced solid tumors that have a specific genetic change called a KRAS mutation. The main goals are to find a safe dose and see how the body handles the drug, while al…
Phase: PHASE1 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC